Compare CORT & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | BXSL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.5B |
| IPO Year | 2001 | 2018 |
| Metric | CORT | BXSL |
|---|---|---|
| Price | $111.86 | $24.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $96.50 | $27.18 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 0.15 |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | N/A |
| Revenue Next Year | $26.98 | N/A |
| P/E Ratio | $1,267.14 | ★ $161.77 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $22.47 |
| 52 Week High | $122.21 | $30.36 |
| Indicator | CORT | BXSL |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 61.37 |
| Support Level | $76.41 | $23.08 |
| Resistance Level | $122.21 | $24.63 |
| Average True Range (ATR) | 5.21 | 0.49 |
| MACD | 0.55 | 0.16 |
| Stochastic Oscillator | 72.40 | 95.53 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.